Replies to post #102809 on Biotech Values

[AlpineBV_Miller]

Ixebepilone, which sees very little use in 3rd line BCa from what I'm told, is likely the reason why this got hung up.

[jq1234]

I thought that Avastin was also approved in 2nd and 3rd line MBC and it is Avastin that is in trouble with the FDA in this area.

Avastin got accelerated approval in 1st line MBC for her2- in combination with paclitaxel. T-DM1 is for her2+.